Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

2,707 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Oxidative Phosphorylation Is a Metabolic Vulnerability in Chemotherapy-Resistant Triple-Negative Breast Cancer.
Evans KW, Yuca E, Scott SS, Zhao M, Paez Arango N, Cruz Pico CX, Saridogan T, Shariati M, Class CA, Bristow CA, Vellano CP, Zheng X, Gonzalez-Angulo AM, Su X, Tapia C, Chen K, Akcakanat A, Lim B, Tripathy D, Yap TA, Francesco MED, Draetta GF, Jones P, Heffernan TP, Marszalek JR, Meric-Bernstam F. Evans KW, et al. Among authors: lim b. Cancer Res. 2021 Nov 1;81(21):5572-5581. doi: 10.1158/0008-5472.CAN-20-3242. Epub 2021 Sep 13. Cancer Res. 2021. PMID: 34518211 Free PMC article.
Genetic and Pharmacological Screens Converge in Identifying FLIP, BCL2, and IAP Proteins as Key Regulators of Sensitivity to the TRAIL-Inducing Anticancer Agent ONC201/TIC10.
Allen JE, Prabhu VV, Talekar M, van den Heuvel AP, Lim B, Dicker DT, Fritz JL, Beck A, El-Deiry WS. Allen JE, et al. Among authors: lim b. Cancer Res. 2015 Apr 15;75(8):1668-74. doi: 10.1158/0008-5472.CAN-14-2356. Epub 2015 Feb 13. Cancer Res. 2015. PMID: 25681273 Free PMC article.
Comprehensive Two- and Three-Dimensional RNAi Screening Identifies PI3K Inhibition as a Complement to MEK Inhibitor AS703026 for Combination Treatment of Triple-Negative Breast Cancer.
Lee J, Galloway R, Grandjean G, Jacob J, Humphries J, Bartholomeusz C, Goodstal S, Lim B, Bartholomeusz G, Ueno NT, Rao A. Lee J, et al. Among authors: lim b. J Cancer. 2015 Oct 28;6(12):1306-19. doi: 10.7150/jca.13266. eCollection 2015. J Cancer. 2015. PMID: 26640591 Free PMC article.
Current challenges of metastatic breast cancer.
Lim B, Hortobagyi GN. Lim B, et al. Cancer Metastasis Rev. 2016 Dec;35(4):495-514. doi: 10.1007/s10555-016-9636-y. Cancer Metastasis Rev. 2016. PMID: 27933405 Review.
Identification of frequent somatic mutations in inflammatory breast cancer.
Matsuda N, Lim B, Wang Y, Krishnamurthy S, Woodward W, Alvarez RH, Lucci A, Valero V, Reuben JM, Meric-Bernstam F, Ueno NT. Matsuda N, et al. Among authors: lim b. Breast Cancer Res Treat. 2017 Jun;163(2):263-272. doi: 10.1007/s10549-017-4165-0. Epub 2017 Feb 27. Breast Cancer Res Treat. 2017. PMID: 28243898
MEK and PI3K catalytic activity as predictor of the response to molecularly targeted agents in triple-negative breast cancer.
Sato N, Wakabayashi M, Nakatsuji M, Kashiwagura H, Shimoji N, Sakamoto S, Ishida A, Lee J, Lim B, Ueno NT, Ishihara H, Inui T. Sato N, et al. Among authors: lim b. Biochem Biophys Res Commun. 2017 Aug 5;489(4):484-489. doi: 10.1016/j.bbrc.2017.05.177. Epub 2017 May 30. Biochem Biophys Res Commun. 2017. PMID: 28576487 Free article.
2,707 results